Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Clinical Trial ID NCT00133224

Rank	Title	Journal	Year	PubWeight™‹?›
1	The changing therapeutic landscape of castration-resistant prostate cancer.	Nat Rev Clin Oncol	2011	1.55
2	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
3	Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.	BMC Cancer	2008	1.04
4	Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.	J Clin Oncol	2013	0.87
5	Emerging targeted therapies for castration-resistant prostate cancer.	Front Endocrinol (Lausanne)	2012	0.81
6	Research in castration-resistant prostate cancer: what does the future hold?	Curr Oncol	2010	0.79
7	Diffuse primary leptomeningeal melanocytosis in a patient receiving a novel cancer cell vaccine for prostate cancer.	BMJ Case Rep	2010	0.79
8	Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.	Onco Targets Ther	2011	0.78
9	Application of radiation technology in vaccines development.	Clin Exp Vaccine Res	2015	0.78
10	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.	Oncoimmunology	2015	0.75